CN112789292A - 对cd137和pd-l1特异性的新型融合蛋白 - Google Patents

对cd137和pd-l1特异性的新型融合蛋白 Download PDF

Info

Publication number
CN112789292A
CN112789292A CN201980050587.8A CN201980050587A CN112789292A CN 112789292 A CN112789292 A CN 112789292A CN 201980050587 A CN201980050587 A CN 201980050587A CN 112789292 A CN112789292 A CN 112789292A
Authority
CN
China
Prior art keywords
ser
leu
asp
lys
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050587.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·帕夫利杜
L·帕塔里尼
A·斯科勒-达希雷尔
C·罗特
S·奥威尔
R·贝莱巴
M·欣纳
J·佩珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Les Laboratoires Servier SAS
Original Assignee
Pieris Pharmaceuticals GmbH
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH, Les Laboratoires Servier SAS filed Critical Pieris Pharmaceuticals GmbH
Publication of CN112789292A publication Critical patent/CN112789292A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980050587.8A 2018-07-31 2019-07-31 对cd137和pd-l1特异性的新型融合蛋白 Pending CN112789292A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18186445.5 2018-07-31
EP18204548.4 2018-11-06
EP18204548 2018-11-06
PCT/EP2019/070596 WO2020025659A1 (en) 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1

Publications (1)

Publication Number Publication Date
CN112789292A true CN112789292A (zh) 2021-05-11

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050587.8A Pending CN112789292A (zh) 2018-07-31 2019-07-31 对cd137和pd-l1特异性的新型融合蛋白

Country Status (28)

Country Link
US (1) US20210363257A1 (https=)
EP (2) EP4249064A3 (https=)
JP (1) JP7482488B2 (https=)
KR (1) KR20210040103A (https=)
CN (1) CN112789292A (https=)
AU (1) AU2019315703A1 (https=)
BR (1) BR112020025263A2 (https=)
CA (1) CA3100119A1 (https=)
CL (1) CL2021000207A1 (https=)
CY (1) CY1126148T1 (https=)
DK (1) DK3830120T5 (https=)
ES (1) ES2948717T3 (https=)
FI (1) FI3830120T3 (https=)
HR (1) HRP20230590T2 (https=)
HU (1) HUE062320T2 (https=)
IL (1) IL279541A (https=)
LT (1) LT3830120T (https=)
MD (1) MD3830120T3 (https=)
MX (1) MX2021000401A (https=)
MY (1) MY200710A (https=)
PH (1) PH12021550001A1 (https=)
PL (1) PL3830120T3 (https=)
RS (1) RS64343B9 (https=)
SG (1) SG11202100989UA (https=)
SI (1) SI3830120T1 (https=)
TW (1) TWI837156B (https=)
WO (1) WO2020025659A1 (https=)
ZA (1) ZA202100125B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115677858A (zh) * 2021-07-23 2023-02-03 合肥瀚科迈博生物技术有限公司 一种能够靶向cd137和pd-l1的双特异性抗体的用途
CN116211860A (zh) * 2023-05-10 2023-06-06 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物
WO2023174140A1 (zh) * 2022-03-17 2023-09-21 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
US11466086B2 (en) 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB
WO2022082005A1 (en) * 2020-10-16 2022-04-21 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
CA3203718A1 (en) * 2021-01-08 2022-07-14 Jiawang Liu Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
KR20250071257A (ko) * 2022-09-21 2025-05-21 씨젠 인크. Cd137 및 cd228에 특이적인 신규한 융합 단백질

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177762A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017215590A1 (en) * 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
CN107922503A (zh) * 2016-03-04 2018-04-17 四川科伦博泰生物医药股份有限公司 一种pdl‑1抗体、其药物组合物及其用途
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US20180148485A1 (en) * 2015-05-18 2018-05-31 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
KR20170138574A (ko) * 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
KR102678252B1 (ko) * 2017-09-01 2024-06-26 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 재조합 이중특이적 항체
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177762A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107820500A (zh) * 2015-05-04 2018-03-20 皮里斯制药有限公司 Cd137特异性的蛋白
US20180148484A1 (en) * 2015-05-04 2018-05-31 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
US20180148485A1 (en) * 2015-05-18 2018-05-31 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
WO2017123650A2 (en) * 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
CN107922503A (zh) * 2016-03-04 2018-04-17 四川科伦博泰生物医药股份有限公司 一种pdl‑1抗体、其药物组合物及其用途
WO2017215590A1 (en) * 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115677858A (zh) * 2021-07-23 2023-02-03 合肥瀚科迈博生物技术有限公司 一种能够靶向cd137和pd-l1的双特异性抗体的用途
WO2023174140A1 (zh) * 2022-03-17 2023-09-21 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
CN116211860A (zh) * 2023-05-10 2023-06-06 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Also Published As

Publication number Publication date
MD3830120T3 (ro) 2023-11-30
BR112020025263A2 (pt) 2021-03-09
CA3100119A1 (en) 2020-02-06
HUE062320T2 (hu) 2023-10-28
IL279541A (en) 2021-01-31
HRP20230590T2 (hr) 2024-02-16
CL2021000207A1 (es) 2021-08-13
KR20210040103A (ko) 2021-04-12
EP3830120B1 (en) 2023-05-24
RS64343B9 (sr) 2023-11-30
HRP20230590T1 (hr) 2023-09-15
RS64343B1 (sr) 2023-08-31
SG11202100989UA (en) 2021-02-25
CY1126148T1 (el) 2023-11-15
EP3830120A1 (en) 2021-06-09
US20210363257A1 (en) 2021-11-25
EP3830120B9 (en) 2023-08-30
MD3830120T2 (ro) 2023-08-31
WO2020025659A1 (en) 2020-02-06
PH12021550001A1 (en) 2021-09-27
LT3830120T (lt) 2023-07-10
FI3830120T3 (fi) 2023-06-13
DK3830120T3 (da) 2023-06-26
MY200710A (en) 2024-01-12
EP4249064A3 (en) 2023-12-06
JP2021533203A (ja) 2021-12-02
TWI837156B (zh) 2024-04-01
DK3830120T5 (da) 2024-08-19
SI3830120T1 (sl) 2023-10-30
AU2019315703A1 (en) 2020-12-10
EP4249064A2 (en) 2023-09-27
TW202019967A (zh) 2020-06-01
ES2948717T3 (es) 2023-09-18
PL3830120T3 (pl) 2023-10-09
MX2021000401A (es) 2021-03-25
ZA202100125B (en) 2023-06-28
JP7482488B2 (ja) 2024-05-14

Similar Documents

Publication Publication Date Title
EP3830120B9 (en) Novel fusion protein specific for cd137 and pd-l1
CN113474359B (zh) 对cd137和gpc3特异性的新型融合蛋白
US20210403516A1 (en) Anti-cancer fusion polypeptide
KR20230020443A (ko) 4-1bb 표적화 다량체 면역조절제
KR20250071257A (ko) Cd137 및 cd228에 특이적인 신규한 융합 단백질
HK40053668A (en) Novel fusion protein specific for cd137 and pd-l1
RU2818349C2 (ru) Новый слитый белок, специфичный для cd137 и pd-l1
RU2814653C2 (ru) Новые слитые белки, специфические в отношении cd137 и gpc3
EA046634B1 (ru) Новый слитый белок, специфичный к cd137 и pd-l1
HK40044273A (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273B (en) Novel fusion protein specific for cd137 and pd-l1
WO2023089079A1 (en) Novel fusion protein specific for ox40 and pd-l1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053668

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210511

WD01 Invention patent application deemed withdrawn after publication